2025
Geographic patterns in wildland fire exposures and county-level lung cancer mortality in the United States
Remigio R, Buller I, Bogle M, Kamenetsky M, Ammons S, Bell J, Fisher J, Freedman N, Jones R. Geographic patterns in wildland fire exposures and county-level lung cancer mortality in the United States. International Journal Of Health Geographics 2025, 24: 8. PMID: 40217528, DOI: 10.1186/s12942-025-00394-x.Peer-Reviewed Original ResearchMeSH KeywordsEnvironmental ExposureFemaleHumansLung NeoplasmsMaleMiddle AgedMortalityUnited StatesWildfiresConceptsLung cancer mortality ratesLung cancer mortalityCigarette smoking prevalenceCancer mortalityWestern USSmoking prevalenceBurned land areasNational Center for Health StatisticsCenter for Health StatisticsLand areaExposure-response assessmentLee's L statisticGeographic patternsMid‐Appalachian regionCombustion by-productsConterminous United StatesSex-specificUnited StatesHealth StatisticsEvaluate geographic patternsWildland firesPoisson regressionMultiple comparisonsUS countiesBivariate associationsMediators of Racial Inequities in Non‐Small Cell Lung Cancer Care
Hamid S, Lee D, Herrin J, Yu J, Pollack C, Dean L, Gaddy J, Oladele C, Feder S, Canavan M, Nunez-Smith M, Soulos P, Gross C. Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care. Cancer Medicine 2025, 14: e70757. PMID: 40052387, DOI: 10.1002/cam4.70757.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancer carePhase of careSocioeconomic statusNon-small cell lung cancerIndividual-level socioeconomic statusNeighborhood-level socioeconomic statusMedicare-Medicaid dual eligibilityWhite patientsHealth care accessLung cancer careNon-Hispanic blacksIndirect effects of mediatorsDiagnosis stageStage-appropriate treatmentTwo-year survivalCancer careCare accessEffects of raceOptimal careDual eligiblesCareStructural racismRacial inequalityBlack patientsInadequate evaluationTop advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approachLung Cancer Screening and Incidental Findings: A Research Agenda: An Official American Thoracic Society Research Statement.
Henderson L, Kim R, Tanner N, Tsai E, Begnaud A, Dako F, Gieske M, Kallianos K, Richman I, Sakoda L, Schwartz R, Yeboah J, Fong K, Lam S, Lee P, Pasquinelli M, Smith R, Triplette M, Tanoue L, Rivera M. Lung Cancer Screening and Incidental Findings: A Research Agenda: An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 436-451. PMID: 39928329, PMCID: PMC11936151, DOI: 10.1164/rccm.202501-0011st.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyManagement of incidental findingsLung cancer screeningCancer screeningThree-round modified Delphi processReporting of incidental findingsClinically significant IFsPrioritized questionsDelphi processIncidental findingClinicians' effortsMultidisciplinary panelPatient anxietyResearch questionsPotential harmLDCT examinationsCoronary artery calcificationIncreased awarenessSignificant IFsExcess costsHarmPotential benefitsArtery calcificationKnowledge gapsComputed tomographyDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerProgrammed cell death ligand 1Eastern Cooperative Oncology Group performance statusData cut-offLong-term efficacyIndividual patient-level dataMedian OSPembrolizumab monotherapySurvival rateProgressive diseaseDiscontinued treatment due to progressive diseaseTreated with first-line pembrolizumabClinical trialsPredictors of 5-year survivalFirst-line pembrolizumab monotherapyCell death ligand 1Pre-existing autoimmune diseaseFirst-line pembrolizumabKEYNOTE-024 trialPD-L1 TPSPermanently discontinue treatmentDeath-ligand 1Efficacy of pembrolizumabMedian follow-upHierarchical Multi‐Label Classification With Gene‐Environment Interactions in Disease Modeling
Li J, Zhang Q, Ma S, Fang K, Xu Y. Hierarchical Multi‐Label Classification With Gene‐Environment Interactions in Disease Modeling. Statistics In Medicine 2025, 44: e10330. PMID: 39865593, DOI: 10.1002/sim.10330.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsComputer SimulationGene-Environment InteractionHumansLung NeoplasmsModels, StatisticalConceptsHierarchical multi-label classificationMulti-label classificationGene-environment interaction analysisGene-environmentEfficient expectation-maximizationGene-environment interactionsSemi-supervised scenariosCancer Genome AtlasUnlabeled dataInteraction analysisExpectation-maximizationGenome AtlasSuperior performanceHierarchical responseDisease outcomeClassificationPenalized estimatorsPractice settingsDisease modelsBiomedical studiesAnalysis literatureE effectsBayesian Modeling of Cancer Outcomes Using Genetic Variables Assisted by Pathological Imaging Data
Im Y, Li R, Ma S. Bayesian Modeling of Cancer Outcomes Using Genetic Variables Assisted by Pathological Imaging Data. Statistics In Medicine 2025, 44: e10350. PMID: 39840672, PMCID: PMC11774474, DOI: 10.1002/sim.10350.Peer-Reviewed Original ResearchProspective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, Grigoriadis K, Lu W, Veeriah S, Naceur-Lombardelli C, Magno N, Ward S, Frankell A, Hill M, Colliver E, de Carné Trécesson S, East P, Malhi A, Snell D, O’Neill O, Leonce D, Mattsson J, Lindberg A, Micke P, Moldvay J, Megyesfalvi Z, Dome B, Fillinger J, Nicod J, Downward J, Szallasi Z, Hackshaw A, Jamal-Hanjani M, Kanu N, Birkbak N, Swanton C. Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nature Cancer 2025, 6: 86-101. PMID: 39789179, PMCID: PMC11779643, DOI: 10.1038/s43018-024-00883-1.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaStage I diseaseClinicopathological risk factorsSurvival of patientsResponse to treatmentRNA sequencing dataI diseaseSequence dataMetastatic clonesNeedle biopsyIndividual tumorsLung expressionTranscription signalsPrognostic informationWhole exomeExpressed genesChemotherapy sensitivityProspective validationSurvival associationsTranscriptomic heterogeneityHuman tumorsEvolutionary measuresChromosomal instabilityRisk factorsNatural historySensitivity to Environmental Stress and Adversity and Lung Cancer
Chen Y, Lan Q, Yu J, Godbole D, Byun J, Amos C, Zhang H. Sensitivity to Environmental Stress and Adversity and Lung Cancer. JAMA Network Open 2025, 8: e2457079. PMID: 39878978, PMCID: PMC11780474, DOI: 10.1001/jamanetworkopen.2024.57079.Peer-Reviewed Original ResearchConceptsLung cancer riskAssociated with lung cancer riskInternational Lung Cancer ConsortiumIndividuals of European ancestryCancer riskGenetic association studiesMendelian randomizationCross-ancestryCancer ConsortiumAssociation studiesInfluence lung cancer riskIncreased risk of lung cancerEuropean ancestryRisk of lung cancerGenome-wide meta-analysisIncreased riskGenome-wide association studiesLung cancer casesIndividuals of African ancestryIndividuals of East Asian ancestryEast Asian ancestryUK BiobankPsychosocial factorsMain OutcomesCancer cases
2024
TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling
Lu W, Zalmas L, Bailey C, Black J, Martinez-Ruiz C, Pich O, Gimeno-Valiente F, Usaite I, Magness A, Thol K, Webber T, Jiang M, Saunders R, Liu Y, Biswas D, Ige E, Aerne B, Grönroos E, Venkatesan S, Stavrou G, Karasaki T, Al Bakir M, Renshaw M, Xu H, Schneider-Luftman D, Sharma N, Tovini L, Jamal-Hanjani M, McClelland S, Litchfield K, Birkbak N, Howell M, Tapon N, Fugger K, McGranahan N, Bartek J, Kanu N, Swanton C. TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling. Nature Cell Biology 2024, 27: 154-168. PMID: 39738653, PMCID: PMC11735399, DOI: 10.1038/s41556-024-01558-w.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAnimalsCadherinsCarcinoma, Non-Small-Cell LungCell Line, TumorChromosomal InstabilityGene Expression Regulation, NeoplasticHippo Signaling PathwayHumansLung NeoplasmsMiceMitosisProtein Serine-Threonine KinasesSignal TransductionTranscription FactorsYAP-Signaling ProteinsConceptsWhole-genome doublingStructural chromosome instabilityChromosomal instabilityHomologous recombinationNumerical chromosome instabilityNon-small-cell lung cancerHR deficiencyPersistent replication stressGenome doublingRadial chromosomesHippo signalingReplication stressChromosomal translocationsEvolutionary adaptationDriver eventsGenetic alterationsFAT1Increased tumor heterogeneityChromosomeCO depletionYAP1Downstream mechanismsRepair deficiencyIntratumour heterogeneityExperimental approachEstimated exposure to endotoxin and circulating immunological markers among male farmers in the Biomarkers of Exposure and Effect in Agriculture study
Ezennia S, Freeman L, Chang V, Xie S, Sandler D, Andreotti G, Parks C, Friesen M, Hofmann J. Estimated exposure to endotoxin and circulating immunological markers among male farmers in the Biomarkers of Exposure and Effect in Agriculture study. Occupational And Environmental Medicine 2024, 81: 635-638. PMID: 39746796, PMCID: PMC11821429, DOI: 10.1136/oemed-2024-109646.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAgricultureBiomarkersChemokine CCL20EndotoxinsFarmersHumansIowaLung NeoplasmsMaleMiddle AgedOccupational ExposureConceptsExposure to endotoxinImmune markersAssociated with reduced lung cancer riskEndotoxin exposureEstimated geometric mean ratiosCirculating immune markersMacrophage-derived chemokine/CCL22Reduced risk of lung cancerLevels of fibroblast growth factor-2Decreased levelsMultiplex bead-based assayRisk of lung cancerExposure-response mannerExposed to endotoxinAssociated with increased levelsLung cancer riskFibroblast growth factor-2Immunological alterationsGrowth factor 2Serum levelsImmunological markersSIL-4RLung cancerBead-based assayMultivariate linear regressionHypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, de Miguel F, Knight J, López-Giráldez F, Choi H, Socci N, Merghoub T, Awad M, Getz G, Gainor J, Hellmann M, Caron É, Kaech S, Politi K. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer. Journal Of Experimental Medicine 2024, 222: e20231106. PMID: 39585348, PMCID: PMC11602551, DOI: 10.1084/jem.20231106.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsNon-small cell lung cancerAcquired resistanceCheckpoint inhibitorsResistant tumorsPatients treated with anti-PD-1/PD-L1 therapyAnti-PD-1/PD-L1 therapyLung cancerResistance to immune checkpoint inhibitorsAssociated with decreased progression-free survivalHypoxia activated pro-drugsTargeting hypoxic tumor regionsTreat non-small cell lung cancerAnti-CTLA-4Anti-PD-1Immune checkpoint inhibitionTumor metabolic featuresProgression-free survivalCell lung cancerResistant cancer cellsHypoxic tumor regionsMHC-II levelsRegions of hypoxiaKnock-outCheckpoint inhibitionGrowth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trialsG9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1
Exposito F, Redrado M, Serrano D, Calabuig-Fariñas S, Bao-Caamano A, Gallach S, Jantus-Lewintre E, Diaz-Lagares A, Rodriguez-Casanova A, Sandoval J, San Jose-Eneriz E, Garcia J, Redin E, Senent Y, Leon S, Pio R, Lopez R, Oyarzabal J, Pineda-Lucena A, Agirre X, Montuenga L, Prosper F, Calvo A. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Cell Death & Disease 2024, 15: 787. PMID: 39488528, PMCID: PMC11531574, DOI: 10.1038/s41419-024-07156-w.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNon-small cell lung cancer patientsCM-272Treatment of non-small cell lung cancerReprogram tumor cellsAssociated with poor prognosisResponse to chemotherapyCell lung cancerCancer drugsMonitor tumor progressionOverexpression of G9aNSCLC cell linesLung cancer growthCancer drug sensitivityNon-small cell lung cancer growthNon-invasive biomarkersTumor volumeAntitumor efficacyTargeted therapyPoor prognosisCancer modelsTumor cellsInduce cell deathTumor progressionLung cancerModeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencingTranscriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors
McGuire C, Meehan A, Couser E, Bull L, Minor A, Kuhlmann-Hogan A, Kaech S, Shaw R, Eichner L. Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2317694121. PMID: 39388266, PMCID: PMC11494357, DOI: 10.1073/pnas.2317694121.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesCell Line, TumorChemokine CXCL10Gene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHistone DeacetylasesHumansLung NeoplasmsMiceMutationProto-Oncogene Proteins p21(ras)PyridinesPyridonesPyrimidinonesT-LymphocytesTranscription, GeneticTumor MicroenvironmentConceptsT cell recruitmentLung tumorsHistone deacetylase 3Enhanced T cell recruitmentCombined treatmentLung tumors in vivoGenetically engineered mouse modelsT cell exclusionInhibition of histone deacetylase 3Tumor immune microenvironmentTumor growth controlKRAS mutant lung tumorsTumors in vivoLung cancer cellsImmune microenvironmentT cellsTissue-specific fashionMouse modelPathway inhibitorTumorPharmacological inhibitionCancer cellsFunction in vivoTranscriptional regulationTranscriptional repressionOutcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT)
Bertolaccini L, Ciani O, Lucchi M, Zaraca F, Bertani A, Crisci R, Spaggiari L, Group L. Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT). JMIR Research Protocols 2024, 13: e57183. PMID: 39378423, PMCID: PMC11496920, DOI: 10.2196/57183.Peer-Reviewed Original ResearchConceptsLocally advanced lung cancerNon-small cell lung cancerOutcomes of patientsAdvanced lung cancerLung cancerWeb-based registryINTERNATIONAL REGISTERED REPORT IDENTIFIERObservational studySecondary objectivesSuboptimal response ratesEvolving treatment paradigmCell lung cancerLung cancer managementTraditional open surgeryInfluence treatment strategiesStudy's secondary objectivePatient-reported outcomesNational benchmarksOpen surgeryProcess of care indicatorsRisk-adjusted outcomesTreatment paradigmNSCLC treatmentCancer managementFollow-upA Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer
Morgensztern D, Ready N, Johnson M, Dowlati A, Choudhury N, Carbone D, Schaefer E, Arnold S, Puri S, Piotrowska Z, Hegde A, Chiang A, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson R, Hingorani P, Jeng E, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer. Clinical Cancer Research 2024, 30: 5042-5052. PMID: 39287821, PMCID: PMC11565168, DOI: 10.1158/1078-0432.ccr-24-1547.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRelapsed/refractory small cell lung cancerTreatment-emergent adverse eventsCell lung cancerAdverse eventsLung cancerVeno-occlusive liver diseaseAntitumor activityResponse rateMedian response durationProgression-free survivalMaximum tolerated doseDose-expansion cohortPhase I studyIncreased aspartate aminotransferaseAntibody-drug conjugatesWeeks' monotherapyDose escalationPrior therapyTolerated doseMedian ageResponse durationLiver diseaseMonotherapyPatientsA Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care
Hakim H, Alexander C, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. A Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care. The Permanente Journal 2024, 28: 212-222. PMID: 39269215, PMCID: PMC11404665, DOI: 10.7812/tpp/23.152.Peer-Reviewed Original ResearchConceptsShared decision-makingOncology cliniciansSDM principlesPerceptions of shared decision-makingImprove health care outcomesPatient-centred care modelComprehensive cancer care centerLeadership buy-inPatient-centered careHealth care outcomesLung cancer careParticipants perceived benefitsHealth care environmentTeam member rolesNon-small cell lung cancer careThematic analysis of interview dataCancer care centerSimulation-based programAnalysis of interview dataCare modelCare outcomesCancer carePatient-centeredPatient experienceCare environmentBuilding Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program
Alexander C, Hakim H, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. Building Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program. The Permanente Journal 2024, 28: 200-211. PMID: 39269220, PMCID: PMC11404653, DOI: 10.7812/tpp/23.160.Peer-Reviewed Original ResearchConceptsShared decision-makingPractice settingsImplementation of shared decision-makingSDM trainingTraining programSimulation training programMultidisciplinary cliniciansCentered carePatient goalsPost-trainingClinician experienceFocus groupsClinical careSelf-efficacyParticipants' understandingClinician awarenessPostinterventionPilot studyActive participationParticipantsProgram designCareCliniciansBody of evidenceGrowing body of evidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply